

Curriculum Vitae **Sidney M. Wolfe, M.D.**

B.S., Chemistry, Case Western Reserve University, Cleveland, OH 1960
(Cornell University, 1955-1959)

M.D., Case Western Reserve University, Cleveland, OH 1965

Intern (Internal Med.), Cleveland Metropolitan General Hospital, Cleveland, OH 1965-66

Clinical Associate, Section on Physiology and Clinical Nutrition, National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, MD. 1966-69

Resident (Internal Med.), Cleveland Metropolitan General Hospital 1969-70

Senior Staff Fellow, Section on Physiology and Clinical Nutrition, National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, MD. 1970-72

Director, Public Citizen Health Research Group, Washington, DC 1972-Present

Consultant, N.I.H., Bethesda, MD, Member, Carcinogenesis Clearinghouse, National Cancer Institute 1976-1978

Member, Joint Coordinating Council for Project Sleep: The National Program on Insomnia and Sleep Disorders 1979-1980

President, Public Citizen, Inc., Washington, DC 1980-1982

Visiting Professor, Cornell University, Hospital Administration Program, Ithaca, NY. 1982-Present

Consultant, National Cancer Institute, DES Task Force Bethesda, MD 1985

Recipient, MacArthur Foundation Fellowship 1990

Member, Society for General Internal Medicine Present

Adjunct Professor of Medicine, Case Western Reserve 1995-Present

University, School of Medicine, Cleveland, OH

Senior Associate, Department of Health Policy & Management, Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD 1995-Present

Areas of Previous Clinical Research

- 1) Clinical and physiological studies of etiology and treatment of alcohol withdrawal syndrome.
- 2) Laboratory studies of mechanism of secretion of mammalian cells; platelet metabolism and cellular mechanisms of blood clotting.

Public Citizen Health Research Group Activities

Public Citizen is a non-profit citizen research, lobbying and litigation organization founded in 1971 by Ralph Nader and Dr. Sidney M. Wolfe. The Health Research Group, one of five affiliated arms of Public Citizen, fights for protection against unsafe drugs, foods, medical devices and workplaces, and for greater consumer control over health decisions.

Health Research Group Books/Reports

1. Ramirez de Arellano, A., Wolfe, S. *Unsettling Scores: A Ranking of State Medicaid Programs*. Public Citizen Health Research Group, 2007.
2. Wolfe, S. Drug ads masquerading as news: letter to 258 local television station general managers and news directors in the country's top-30 television markets.
3. Blalock, K, Wolfe S. *Questionable Hospitals: 527 Hospitals that Violated the Emergency Medical Treatment and Labor Act: A Detailed Look at APatient Dumping*, ≅ Public Citizen Health Research Group, 2001.
4. Wolfe, S., McCarthy, P., Bame, A., Marcus-Adler, B. *20,125 Questionable Doctors Disciplined by State and Federal Governments*, Public Citizen Health Research Group, 2000.
5. Wolfe, S., Sasich, L., Lurie, P., Hope, R. *Worst Pills Best Pills*, Public Citizen Health Research Group, 1988. Fourth edition, 2005. Simon and Schuster/Pocket Books
6. Lurie, P., Wolfe, S. *FDA Medical Officers Report Lower Standards Permit Dangerous Drug Approvals*, Public Citizen Health Research Group, 1998
7. Wolfe, S., Franklin, K., McCarthy, P., Bame, A., Marcus-Adler B. *16,638 Questionable Doctors Disciplined by States or the Federal Government*,

- Public Citizen Health Research Group, 1998.
8. Dehlendorf, C., Wolfe, S. *Physicians Disciplined for Sex-Related Offenses*, Public Citizen Health Research Group, 1997
 9. Wolfe, S., Gabay, M., McCarthy, P., Bame, A., Marcus-Adler, B. *13,012 Questionable Doctors Disciplined by States or the Federal Government*, Public Citizen Health Research Group, 1996.
 10. Gabay, M., Wolfe, S. *Delivering a Better Childbirth Experience* (2 reports: Consumer Guide & Policy Report), Public Citizen's Health Research Group, 1995.
 11. Wolfe, S., Johnson, Diann. *Medical Records: Getting Yours*, Public Citizen's Health Research Group, 1995.
 12. Wolfe, S., Gabay, M. *Unnecessary Cesarean Sections: Curing a National Epidemic*, Public Citizen's Health Research Group, 1994.
 13. Wolfe, S., McCarthy, P., Bame, A., McKnew, L. *10,289 Questionable Doctors Disciplined by States or the Federal Government*, Public Citizen Health Research Group, 1993.
 14. Wolfe, S., Hope RE. *Worst Pills Best Pills II: An Older Adults Guide to Avoiding Drug Induced Death or Illness*, Public Citizen Health Research Group 1993.
 15. Torrey, E., Stieber, J., Ezekiel, J., Wolfe, S., Sharfstein, J., Noble, J., Flynn, L. *Criminalizing the Seriously Mentally Ill: The Abuse of Jails as Mental Hospitals*, Public Citizen Health Research Group and the National Alliance for the Mentally Ill, 1992.
 16. Samuels, B., Wolfe S. *Medical Records: Getting Yours: A Consumer's Guide to Obtaining and Understanding the Medical Record*, Public Citizen Health Research Group, 1992.
 17. VanTuinen, I., Wolfe, S. *Unnecessary Cesarean Sections: Halting a National Epidemic*, Public Citizen Health Research Group, 1992.
 18. Wolfe, S., Jones, R. *Women's Health Alert*, Addison Wesley, 1991.
 19. VanTuinen, I., McCarthy, P., Wolfe S. *9479 Questionable Doctors Disciplined by States or the Federal Government*, Public Citizen Health Research Group, 1991.
 20. Torrey, F., Erdman, K., Wolfe S., Flynn L. *Care of the Seriously Mentally Ill A Rating of State Programs*, Public Citizen Health Research Group and the National Alliance for the Mentally Ill, 1990.
 21. Silver, L., Wolfe S. *Unnecessary Cesarean Sections: How To Cure a National Epidemic*, Public Citizen Health Research Group, 1989.
 22. Torrey, F., Wolfe, S. *Care of the Seriously Mentally Ill A Rating of State Programs*, Public Citizen Health Research Group and the National Alliance for

- the Mentally Ill, 1988.
23. Wolfe, S., Fugate, L., Hulstrand, E., Kamimoto, L., *Worst Pills Best Pills*, Public Citizen Health Research Group, 1988.
 24. Erdman, K., Wolfe, S. *Poor Health Care For Poor Americans: A Ranking of State Medicaid Programs*, Public Citizen Health Research Group, 1987.
 25. Tanio, C., Manley, M., Wolfe, S. *Unnecessary Cesarean Sections A Rapidly Growing National Epidemic*, Public Citizen Health Research Group, 1987.
 26. Torrey, F., Wolfe, S. *Care of the Seriously Mentally Ill A Rating of State Programs*, Public Citizen Health Research Group, 1986.
 27. Kaufman, J., Rabinowitz-Dagi, L., Levin, J., McCarthy, P., Wolfe, S. and Bargmann, E., *Over the Counter Pills That Don't Work*, Public Citizen Health Research Group, 1983.
 28. Bargmann, E., Wolfe, S. and Levin J., *Stopping Valium and Ativan, Centrax, Dalmane, Librium, Paxipam, Restoril, Serax, Tranxene, Xanax*, Public Citizen Health Research Group, 1982.
 29. Wolfe, S., Coley C. and the Health Research Group, *Pills That Don't Work: A Consumers' and Doctors' Guide to 610 Prescription Drugs that Lack Evidence of Effectiveness*, Public Citizen Health Research Group, 1981.
 30. Warner, R., Wolfe, S. and Rich, R., *Off Diabetes Pills: A Diabetic's Guide to a Longer Life*, Public Citizen Health Research Group, November 1978.
 31. Nash, G. and Wolfe, S., *Taking the Pain out of Finding a Good Dentist*, Public Citizen Health Research Group, 1975.

Publications

1. Weisberger, A.S., Armentrout, S., and Wolfe, S.: Protein synthesis by reticulocyte ribosomes, I. Inhibition of polyuridylic acid-induced ribosomal protein synthesis by chloramphenicol. *Proc. Nat. Acad. Sci.* 1963; 50: 86-93.
2. Weisberger, A.S., Wolfe, S., and Armentrout, S.: Inhibition of protein synthesis in mammalian cell-free systems by chloramphenicol. *J. Exp. Med.* 1964; 120: 161-181.
3. Weisberger, A.S. and Wolfe, S.: Effect of chloramphenicol on protein synthesis. *Fed. Proc.* 1964; 23: 976-983.
4. Wolfe, S.M. and Weisberger, A.S.: Protein synthesis by reticulocyte ribosomes, II. The effects of magnesium ion and chloramphenicol on induced protein synthesis. *Proc. Nat. Acad. Sci.* May 1965; 53: 991-998.

5. Wolfe, S.M., Harrah, J.D., Merritt, W.R., Hoye, R.C. and Gordon R.S., Jr.: Radiographic diagnosis of Meckel's diverticulum. *Journal of the American Medical Association*. September 9, 1968; 205(11): 177-178.
6. Frank, A., Roth, J., Wolfe, S., and Metzger, H.: Medical problems of civil disorders. *New Eng. J.Med.* January 30, 1969; 280(5): 247-253.
7. Wolfe, S.M. and Shulman, N.R.: Adenyl cyclase activity in human platelets. *Biochem. & Biophys. Res. Commun.* 1969; 35: 265-272.
8. Wolfe, S.M. and Victor, M.: The relationship of hypomagnesemia and alkalosis to alcohol withdrawal symptoms. *Ann. N.Y. Acad. Sci.* 1969; 162: 973-984.
9. Wolfe, S.M., Mendelson, J., Ogata, M., Victor, M., Marshall, W., and Mello, N.: Respiratory alkalosis and alcohol withdrawal. *Trans. Amer. Assoc. Phys.* 1969; 82: 344-352.
10. Deisseroth, A., Wolfe, S.M., and Shulman, N.R.: Platelet phosphorylase activity in the presence of activators and inhibitors of aggregation. *Biochem. Biophys. Res. Commun.* May 11, 1970; 39(3) 551-557.
11. Wolfe, S.M., and Henkin, R.I.: Absence of taste in type II familial dysautonomia: unresponsiveness to methacholine despite the presence of taste buds. *J. Pediatrics* July 1970; 77: 103-108.
12. Wolfe, S.M., and Shulman, N.R.: Inhibition of platelet energy production and release reaction of PGE₁/theophylline and camp. *Biochem. Biophys. Res. Commun.* October 9, 1970; 40(1): 551-7.
13. Wolfe, S., Cage, G., Epstein, M., Tice, L., Miller, H., and Gordon, R.S., Jr.: Metabolic studies of isolated human eccrine sweat. *J. Clin. Invest.* October 1970; 49: 1880-1884.
14. Cage, G.W., Wolfe, S.M., Thompson, R.H., and Gordon, R.S., Jr.: Effects of water intake on composition of thermal sweat in normal human volunteers. *J. Appl. Physiol.* November 1970; 29: 687-690.
15. Bergmann, Thesi, and Wolfe, S.M.: Observations of the reactions of healthy

children to their chronically-ill siblings. *Bulletin of the Phila. Assoc. for Psychoanalysis*. Sept. 1971; 21: No. 3, 145-161.

16. Wolfe, S.M., and Victor, M.: The physiological basis of the alcohol withdrawal syndrome. In *Recent Advances in Studies in Alcoholism*. Washington, D.C. Government Printing Office, 1971.

17. Wolfe, S., and Nader R.,: New health research group. *New England Journal of Medicine*. Oct 21, 1971; 285(17): 974

18. Droller, M.J., and Wolfe, S.M.: Thrombin-induced increase in intracellular cyclic 3', 5'-adenosine monophosphate in human platelets. *J. Clin. Invest.* 51: 3094-3103, 1972.

19. Droller, M.J. and Wolfe, S.M.: Uncertain Role of CAMP in platelet function. *New England Journal of Medicine* April 27, 1972; 286(17): 948-9.

20. Victor, M., and Wolfe, S.M.: The alcohol withdrawal syndrome: causation and treatment. In *Alcoholism. Progress in Research and Treatment*. Bourne, Peter, and Fox, Ruth (editors). New York, Academic Press. 1973.

21. Wolfe, S.: Breaking the barriers to prevention: the role of the medical profession. *Bull NY Academy of Medicine*, January, 1975; (1): 186-98.

22. Muenzer, J., Weinbach, E.C., and Wolfe, S.M.: Oxygen consumption of human blood platelets, I. Effect of thrombin. *Biochimica et Biophysica Acta*, February 17, 1975; 376 (2): 237-242.

23. Muenzer, J., Weinbach, E.C., and Wolfe, S.M.: Oxygen consumption of human blood platelets, II. Effect of inhibitors on thrombin-induced oxygen burst. *Biochimica et Biophysica Acta*, February 17, 1975; 376(2): 243-248.

24. Wolfe, S.M.: The real victim. *Trial II* 26-28, 1975.

25. Wolfe, S.: Letter: Programs to prevent cancer needed. *New England Journal of Medicine*, September 1975 11; 293(11):561-2.

26. Wolfe, S.M.: The patient as consumer under national health insurance. National Health Insurance. Proceedings of Symposium on National Health Insurance. Los

Angeles, California, University of California, 1976.

27. Wolfe, S.M.: A Case for worker involvement in risk assessment. *Ann. N.Y. Acad. Sci.* 271: 410-412, 1976.

28. Wolfe, S.M.: Standards for carcinogens: science affronted by politics. Cold Spring Harbor conferences on Cell Proliferation, Volume 4: Origins of Human Cancer. Proceedings of Conference Cold Spring Harbor Laboratories, 1976.

29. Wolfe, S.M.: The citizen. Symposium on the handling of toxicological information, Nat. Institute of Health. 171-176, May 27-28, 1976.

30. Bogue, T., and Wolfe, S.M.: CAT scanners: is fancier technology worth a billion dollars of health consumers' money. *Computed Axial Tomography* 1: 59-68, 1977.

31. Wolfe, S. Feminine Straight to the Grave. *Mother Jones*: 18-19, May 1978.

32. Wolfe, S. The New Drop Dead Diet. *Mother Jones*: June 1978.

33. Wolfe, S. What Your Doctor Hides from You. *Mother Jones*: 11-12, August 1978.

34. Wolfe, S. Now, Let the Victim Beware. *Mother Jones*: 14-18, Sept./Oct. 1978.

35. Wolfe, S. The Conflict Between Individual Freedom and Social Control: Saccharin and Food Additives. *Ann N.Y. Acad. Sci.* 329, p.42-245, November, 1979.

36. Wolfe, S. The Dichotomy Between Theory and Practice in Risk/Benefit Analysis. *Ann N.Y. Acad. Sci.* 329, p. 274-276, November 1979.

37. Trobe, J.D., Rubin, M.L. Wolfe, S.M. Recertification. A Continuing Debate. *Survey of Ophthalmology*, Volume 24, No.4, January-February 1980.

38. Wolfe, S. Are Patients in the Dark About Physician Competence?: *The Internist*: p.8-9, March 1981.

39. Wolfe, S. and Bargmann, E. Letter to the Editor concerning Airplanes: Medically Underequipped. *NEJM*, April, 1981; 304; 1049.

40. Wolfe, S. Benoxaprofen. *British Medical Journal* (Clinical Research Edition) 1982: September 18; 285(6344):809.
41. Wolfe, S. Misprescribing: Causes and Remedies. *The Internist*: March 1982.
42. Wolfe, S. The Marketing of a Drug (Selacryn), *Health and Medicine*: p. 31-32, Spring 1982.
43. Wolfe, S. Oraflex: Who Learned? Letter to the Editor, *Washington Post*, Sept. 20, 1982.
44. Wolfe, S. Reagan's Hospital Proposals to Weaken the Quality of Hospital Care. *Journal of Public Health Policy*, Vol. 3, #4, p.371-373, 1982.
45. Behrman, M., Wolfe, S. Heat Stroke and Community Runs (letter). *British Medical Journal* (Clinical Research Edition) 1981 June 20:282(6281): 2060
46. Wolfe, S. Review of Prescriptions for Death: The Drugging of the Third World in *Journal of Public Health Policy*, Vol. 4, #1, p.115-116, 1983.
47. Wolfe, S. Reagan's Hospital Proposals Would Hurt the Old and Poor. Editorial, *New York Times*, October 2, 1982.
48. Wolfe, S. "Non-Prescription Drugs: How Safe?" Editorial, *Los Angeles Times*, October 24, 1983.
49. Wolfe, S. "Unnecessary Surgery Wastes Lives, Money". Editorial, *USA Today*, October 31, 1983.
50. Wolfe, S. Don't Ignore This Danger Signal. Editorial, *USA Today*, November 23, 1983.
51. Bargmann, E. and Wolfe, S. Letter to the Editor concerning Benzodiazepines. *New Eng. J. Med.* 310: 465, 1984.
52. Bargmann, E. and Wolfe, S. Letter to the Editor concerning Long Term Diazepam Therapy. *JAMA* 251: 1555, 1984.
53. Bargmann, E., Greenberg, A., Kowey, P., and Wolfe, S. Letter to the Editor on

Conflicting Views Regarding the Frequency of Unnecessary Pacemaker Implants. *Am. J. Cardiol.* 51: 1042-1043, 1983.

54. Wolfe, S. and Greenberg, A. Letter to the Editor on Bjork-Shiley Convexo-Concave heart valve. *New Eng. J. Med.* 312: 314-315, 1985.

55. Silver, G. and Wolfe, S. Letter to the Editor concerning the malpractice crisis. *New York Times*, May 4, 1985.

56. Wolfe, S. Op Ed article concerning Peer Review Organizations and consumer access to data about hospital performances. *Los Angeles Times*, May 6, 1985.

57. Wolfe, S. Letter to the Editor on safety of piroxicam. *Lancet* 8510: 808-809, 1986.

58. Wolfe, S. Letter to the Editor on Suprofen-induced flank pain and renal failure. *New England J. of Med.* 316: 1025, 1987.

59. Wolfe, S. Editorial entitled "Dangerous Delays in Tampon Absorbency Warnings," concerning FDA's continued failure to require tampon manufacturers to provide absorbency information. *JAMA* 258: 949, 1987.

60. Wolfe, S. Patients for Sale? Editorial, *Washington Post*, October 4, 1987.

61. Wolfe, S., Reducing Medical Malpractice: Tort Law reform is not the key, *Public Health Representative* 1988 July-Aug; 103(4):338.

62. Wolfe, S. Doctors Malpractice Plan Ignites New Conflict. Editorial, *Washington Post*, January 19, 1988.

63. Wolfe, S. New Drugs Can Offer New Threat. Editorial, *USA Today*, August 5, 1988.

64. Holmes, A. and Wolfe S.: When a Uniquely Effective Drug is Teratogenic: The Case of Isotretinoin. Letter, *The New England Journal of Medicine*, 321: 756, 1989.

65. Wolfe, S.: The Right to Know Belatedly Comes to the Health Care System, *The Internist*: 12-14, October 1989.

66. Wolfe, S.: Medical Ethics: A Broader Definition, *The Mount Sinai Journal of Medicine* 1991: 58, No. 5; 455-61.
67. Vladeck, D., Wolfe, S.: The Politics of OSHA's Standard-Setting, *American Journal of Industrial Medicine* 1991: 19; 801-4.
68. Himmelstein, D., Wolfe, S., Woolhandler, S., The Vanishing Health Care Safety Net: New Data on Uninsured Americans, *International Journal of Health Services* 1992: 22(3); 381-96.
69. Wolfe, S.: When Our Hospitals Get Sick. Editorial. *Washington Post*, January 19, 1992.
70. Wolfe, S., Lurie, P.: Letter, Regulation of Benzodiazepine Prescription, *Journal of the American Medical Association*, July 22/29, 1992.
71. Lurie, P., Kahn, J., Wolfe, S. Letter, Regulation of Benzodiazepine Prescription, *Journal of the American Medical Association*, July 22/29, 1992.
72. Wolfe, S., A Public Citizen Health Research Group Perspective On Federal Triplicate Prescription Drugs, *NIDA Res. Monograph.*, 1993: 131; 270-8.
73. Himmelstein, D., Wolfe, S., Woolhandler S. Mangled Competition, *American Prospect*, Spring 1993.
74. Ahmed, R., Wolfe, S., Fluid Losses with Diarrhea, *American Pharmacy*, February, 1993: NS33(2); 5-6.
75. Wolfe, S., The Need for Public Access to the National Practitioner Data Bank, *Federation Bulletin*, Winter 1993.
76. Moore, S., Wolfe, S., Lindes, D., Douglas, C., Epidemiology of Failed Tobacco Control Legislation, *JAMA*, October 19, 1994.
77. Hellander I; Moloo J; Himmelstein DU; Woolhandler S; Wolfe SM., The Growing Epidemic of Uninsurance: New Data on the Health Insurance Coverage of Americans, *International Journal of Health Services*, 1995;25(3): 377-92.
78. Ahmad, S., Wolfe, S. Advertising in Pediatrics (Letters to the Editor Section),

Pediatrics, 95: Volume 4, 617-18, 1995.

79. Wolfe, S., Unhealthy Charities, *Lancet*, January/February 1995.

80. Wolfe, S., Congress Should Open the National Practitioner Data Bank to All, *Public Health Reports*, 1995 July/August, 110(4); 378-9.

81. Wolfe, S., Zieve, Allison. Op-Ed. Don't Weaken the FDA Laws, *Washington Post*, February 28, 1996.

82. Wolfe, S., Perspective on Public Health: Save the Gold Standard, Commentary, *The Los Angeles Times*, July 22, 1996, pg. A11.

83. Wolfe, S., Current FDA "Reform" Would Endanger Americans, *The Journal of NIH Research*, August 1996, Vol. 8; 37-8.

84. Wolfe, SM., Questionable Doctors -- lots of them! *Revolution*, Summer 1996; 6(2): 20-2, 85.

85. Wolfe, S., Drug advertisements that go straight to the hippocampus, *The Lancet*, September 7, 1996, Vol. 348, No. 9028; 632.

86. Wolfe, S., Dame, Lauren. Op-Ed. Truly Radical Mastectomies, *Washington Post*, September 24, 1996.

87. Wolfe, S. Why Do American Drug Companies Spend More than \$12 Billion a Year Pushing Drugs? Is it Education or Promotion?, *The Journal of General Internal Medicine*, October 1996, Vol. 11; 637-9.

88. Wolfe, S., Lurie, Peter. Unethical Trials of Interventions to Reduce Perinatal Transmission of the Human Immunodeficiency Virus in Developing Countries. *NEJM*, September 18, 1997, Vol. 337, Number 12; 853-56.

89. Wolfe, SM., Gabay, M. Nurse-midwifery. The beneficial alternative. *Public Health Reports*, 1997, Sep-Oct; 112(5): 386-94.

90. Wolfe, S., Sasich, Larry. The National Council on Patient Information and Education, Letter to the Editor, *JAMA*, November 12, 1997; Vol. 278, Number 18; 1491-1492.

91. Wolfe, S., Dehlendorf, Christine. Physicians Disciplined for Sex-Related Offenses, *JAMA*, June 17, 1998; Vol. 279, Number 23; 1883-1888.
92. Wolfe, S., Sasich, L & Barbehenn, E. Safety of sildenafil citrate, *The Lancet*, October, 24, 1998; Vol. 352; 1393.
93. Wolfe, S., Lurie, P. Op-Ed. Troubling Climate at FDA, *Washington Post*, December 30, 1998.
94. Wolfe, S. Public Disclosure of Process and Outcome Measures, *Clinical Performance and Quality Health Care*, January/February/March 1999; Vol. 7, Number 1; 38-40.
95. Wolfe, S., Sasich, L. Letter to the Editor. The Wild, Wild Web. *Washington Post*, Health Section, June 1, 1999.
96. Wolfe, S., Lurie, P. Comments in correspondence section in response to article entitled "AScience, ethics, and future of research into maternal-infant transmission of HIV-1", *The Lancet*, May 29, 1999; Vol. 353, Number 9167.
97. Lurie, P., Wolfe, S. Op-Ed. Proposed Revisions to the Declaration of Helsinki: Paving the Way for Globalization in Research, *Western Journal of Medicine*, 1999 July; 171(1):6.
98. Wolfe, S. Promotion of Off-Label Uses of Drugs. Opinion. *USA Today*, August 9, 1999.
99. Wolfe, S., Sasich, L., Lurie, P., & Barbehenn, E. Letter. Information on Thiazolidinediones, *The Lancet*, July 15, 2000; Vol. 356, Number 9225.
100. Wolfe, S., Lurie, P. Letter. Protecting Patients in Medical Research, *The Washington Post*, October 17, 2000.
101. Wolfe, S., Lurie, P., & Barbehenn, E. Letter. Alosetron for Irritable Bowel Syndrome, *The Lancet*, December 9, 2000.
102. Wolfe, S., & Morrison, A. Letter. None of Our Business, and None of Theirs, Either, *The Washington Post*, January 7, 2001.

103. Barbehenn, E., Lurie, P., & Wolfe, S. Letter. Osteosarcoma Risk in Rats Using PTH 1-34, *Trends in Endocrinology & Metabolism*, November, 2001.
104. Wolfe, S., & Lurie, P. Letter. On the Anthrax Front: Fear and Vigilance, *New York Times*, October 24, 2001.
105. Wolfe, S. The Destruction of Medicine by Market Forces: Teaching Acquiescence or Resistance and Change?, *Academic Medicine*, Vol. 77, No. 1, January 2002.
106. Wolfe, S. Direct-To-Consumer Advertising — Education or Emotion Promotion?, *New England Journal of Medicine*, Vol. 346, No. 7, February 14, 2002.
107. Lasser, K., Allen, P., Woolhandler, S., Himmelstein, D., Wolfe, S., Bor, D. Timing of New Black Box Warnings and Withdrawals for Prescription Medications. *Journal of the American Medical Association*, Vol. 287, No. 17, May 1, 2002.
108. McCormick D, Himmelstein DU, Woolhandler S, Wolfe SM, Bor DH. Relationship between low quality-of-care scores and HMOs' subsequent public disclosure of quality-of-care scores. *JAMA*. 2002 Sep 25; 288(12):1484-90.
109. Lurie P, Wolfe SM. Continuing exposure to hexavalent chromium, a known lung carcinogen: an analysis of OSHA compliance inspections, 1990-2000. *Am J Ind Med*. 2002 Nov; 42(5):378-83.
110. Wolfe SM. Drug safety withdrawals: who is responsible for notifying patients? *Pharmacoepidemiol Drug Saf*. 2002 Dec; 11(8):641-2.
111. Wolfe SM. A Free Ride for Bad Doctors. *New York Times*, March 4, 2003.
112. Wolfe SM. Remedies Needed to Address the Pathology in Reporting Adverse Reactions and Food and Drug Administration Use of Reports. *Journal of General Internal Medicine*. 18(1):72 2003 January
113. Wolfe SM. Ephedra Scientific Evidence Versus Money/Politics. *Science*. 2003 April 18; 300:437.

114. Wolfe SM. Democracy by Disclosure: The Rise of Technopopulism (Book Review). *New England Journal of Medicine* 2003 May 8; 348:19.
115. Wolfe S.M. Food and Drug Disaster. *Washington Post*, September 10, 2003.
116. Himmelstein DU, Woolhandler S, Wolfe SM. Administrative waste in the U.S. Health Care System in 2003: the cost to the nation, the states, and the District of Columbia, with state-specific estimates of potential savings. *Int J Health Sciences* 2004; 34:79-86.
117. Tepper OM, Lurie PL, Wolfe SM. Medical Education Courses in Research-Based Health Activism. *Virtual Mentor* 2004 Jan; 6:1.
118. Wolfe, S.M. Dangers of rosuvastatin identified before and after FDA approval. *Lancet*. 2004; 363:2189-90.
119. Ardati A, Stolley P, Knapp DE, Wolfe SM, Lurie P. Statin-associated Rhabdomyolysis. *Pharmacoepidemiol Drug Saf*. 2005 Apr; 14(4):287
120. Woolhandler S, Himmelstein DU, Distajo R, Lasser KE, McCormick D, Bor DH, Wolfe SM. America's neglected veterans: 1.7 million who served have no health coverage. *Int J Health Serv*. 2005; 35(2):313-23.
121. Lurie P, Wolfe SM. Misleading data analyses in salmeterol (SMART) study. *Lancet*. 2005 Oct 8; 366(9493):1261-2
122. Lurie P, Tran T, Wolfe SM, Goodman R. Violations of exhibiting and FDA rules at an American Psychiatric Association annual meeting. *J Public Health Policy*. 2005 Dec; 26(4):389-99
123. Wolfe SM. There have been inadequate warnings that erectile dysfunction drugs can cause blindness. *MedGenMed*. 2005. Dec 5;7(4):61
124. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. *JAMA*. 2006 Apr 26; 295(16):1921-8.
125. Wolfe SM. Schroeder Lecture. Worst pills, Best pills. *Health Matrix Clevel*. 2006 Summer;16(2):785-96.

126. Jung P, Lurie P, Wolfe SM. U.S. physicians disciplined for criminal activity. *Health Matrix Clevel.* 2006 Summer;16(2):335-50.

127. Tapley AL, Lurie P, Wolfe SM Suboptimum use of FDA drug advisory committees. *Lancet.* 2006 Dec 23;368(9554):2210

128. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. *JAMA.* 2007 Mar 21;297(11):1216-23.

129. Natanson C, Kern S, Lurie P, Banks S, Wolfe SM. Cell-Free Hemoglobin-Based Blood Substitutes and Increased Myocardial Infarction and Death. *JAMA.* 2008 May 21: (published online April 28, 2008)

Testimony before Congress, Federal Agencies, Etc.

1. Wolfe, S.: Testimony before the Pennsylvania Blue Shield on Unnecessary Surgery, September 26, 1972.

2. Wolfe, S.: Testimony before the U.S. Department of Labor Hearings on Proposed Sanitation Standards, November 9, 1972.

3. Wolfe, S.: Testimony at APHA Annual Meeting on Occupational Health and Safety: Present Problems, Future Prospects, November 14, 1972.

4. Wolfe, S.: Testimony before the National Council of Churches Drug Advertising Hearings, Nov. 15, 1972.

5. Johnson, A. and Wolfe, S.: Testimony before the Senate Subcommittee on Health on the Morning After Pill (DES), Feb. 22, 1973.

6. Wolfe, S.: Testimony before the U.S. Senate Subcommittee on Health Hearings on Human Experimentation and the "Super Coil" an abortion device, March 7, 1973.

7. Wolfe, S.: Testimony before the Massachusetts State Legislature on Prescription Drug Price Posting, March 8, 1973.

8. Wolfe, S.: Testimony before the Senate Health Subcommittee on Medical Devices, September 14, 1973.

9. Wolfe, S.: Testimony before the Senate Consumer Credit Subcommittee on the Medical Information Bureau, Oct. 3, 1973.
10. Johnson, A., and Wolfe, S.: Testimony before the U.S. House of Representatives Health Subcommittee on Medical Devices, Oct. 23, 1976.
11. Masselli, D., and Wolfe, S.: Testimony before the Consumer Product Safety Commission Public Hearing on the Dangers Associated with the Use of Aerosols, Feb. 20, 1974.
12. Wolfe, S.: Testimony before the U.S. Senate Health Subcommittee Hearings on cosmetic safety, Feb. 21, 1976.
13. Wolfe, S.: Testimony before the U.S. Senate Health Subcommittee on adverse consequences of overprescribed drugs, Feb. 25, 1974.
14. Wolfe, S.: Testimony before the U.S. Senate Health Subcommittee Legislative Hearings on S. 3441 and S. 966, May 21, 1974.
15. Wolfe, S.: Testimony before the U.S. Senate Health Subcommittee on S. 3585, the Health Manpower Amendments to the Public Health Service Act, June 24, 1974.
16. Johnson, A. and Wolfe, S.: Testimony before the U.S. Senate Subcommittee on Health, on proposed vitamin legislation, August 22, 1974.
17. Wolfe, S.: Testimony before the U.S. Senate Commerce Committee on the Consumer Product Safety Commission, Feb. 21, 1975.
18. Wolfe, S.: Testimony before the Subcommittee on Health House Committee on Ways and Means on health insurance for the unemployed, March 3, 1975.
19. Wolfe, S.: Testimony before the Senate Committee on Commerce, Subcommittee on the Environment on the Toxic Substances Control Act, S. 776, March 5, 1975.
20. Wolfe, S.: Testimony before Subcommittee on Health, House, Commerce Committee on Health Insurance for the Unemployed, March 10, 1975.
21. Wolfe, S.: Testimony before the Senate Health Subcommittee Hearings on

Medical Malpractice, April 18, 1975.

22. Wolfe, S.: Testimony before the House Subcommittee on Oversight and Investigations on Unnecessary Surgery, July 15, 1975.

23. Johnson, A. and Wolfe, S.: Testimony before the House Subcommittee on Health on medical device legislation, July 28, 1975.

24. Wolfe, S.: Testimony before the Pennsylvania Dept. of Insurance hearings on Proposed Blue Cross Rate Increase, Sept. 11, 1975.

25. Wolfe, S.: Testimony before the Senate Subcommittee on Alcoholism and Narcotics, March 8, 1975.

26. Wolfe, S.: Testimony before the Senate Subcommittee and Administrative Practices Subcommittee on EPA and the Testing of Pesticides (current use of Shell No-Pest Strip and other DDVP-containing products), April 9, 1976.

27. Johnson, A. and Wolfe, S.: Testimony before House Health Subcommittee hearings on proposed drug safety amendments (H.R. 14289) to the Food, Drug and Cosmetic Act, June 22, 1976.

28. Wolfe, S.: Testimony before House Subcommittee on Health and Long-Term Care on regulation of costs of Medicare reimbursement for "Medical Appliances" for the elderly, June 23, 1976.

29. Johnson, A. and Wolfe, S.: Testimony before the House Health Subcommittee Hearings on proposed legislation to indemnify swine flu vaccine manufacturers, June 29, 1976.

30. Johnson, A. and Wolfe, S.: Testimony before the House Health Subcommittee on the current status of the swine flu vaccine program, July 20, 1976.

31. Johnson, A. and Wolfe, S.: Testimony before the Senate Select Committee on Small Business Hearings on Food Additives, January 13, 1977.

32. Greene, P. and Wolfe, S.: Testimony before the Standards and Policy/Budget Subcommittees on the Proposed OSHA Carcinogen Standard, February 17, 1977.

33. Wolfe, S.: Testimony before the Nuclear Regulatory Commission, on behalf of Public Interest Research Group, on the hazards involved in exposure of workers and the general public to existing levels of plutonium, March 4, 1977.
34. Greene, P., Rosenman, K. and Wolfe, S.: Testimony before U.S. Dept. of Labor Hearings on Proposed Occupational Standard for Lead, March 15, 1977.
35. Johnson, A. and Wolfe, S.: Testimony before Subcommittee on Health, House Commerce Committee Hearings on Saccharin, March 21, 1977.
36. Greene, P. and Wolfe, S.: Testimony before U.S. Dept. of Labor Hearings on Proposed Occupational Standard for Cotton Dust, April 5, 1977.
37. Wolfe, S.: Testimony before the FDA Hearings on Public Citizen's Health Research Petition for Imminent Hazard Ban of Phenformin, May 13, 1977.
38. Johnson, A. and Wolfe, S.: Testimony before Food and Drug Administration Hearings on the Proposed Saccharin Ban, May 18, 1977.
39. Wolfe, S.: Testimony before House Intergovernmental Relations and Human Resources Subcommittee Hearings on the National Cancer Program, June 14, 1977.
40. Johnson, A. and Wolfe, S.: Testimony before the House Health Subcommittee on the Federal swine flu immunization program, Sept. 16, 1977.
41. Greene, P. and Wolfe, S.: Testimony before U.S. Department of Labor hearings on economic protection in the proposed occupational standard for lead, Nov. 8, 1977.
42. Wolfe, S.: Testimony before FDA hearings on legislative proposals regarding drug regulation, Nov. 22, 1977.
43. Bogue, T. and Wolfe, S.: Testimony before HEW hearings on proposed sterilization regulations, Jan. 17, 1978.
44. Wolfe, S.: Testimony before FDA Obstetrics-Gynecology Advisory Committee on DES and breast cancer, Jan. 30, 1978.
45. Wolfe, S. and Bogue, T.: Testimony before House Health Subcommittee on the Health Planning and Resources Development Amendments of 1978 (H.R. 10460), Jan.

31, 1978.

46. Wolfe, S. and Bowring M.A.: Testimony on OSHA's proposed carcinogen policy, Feb. 1978.

47. Wolfe, S. and Bogue, T.: Testimony before the House Oversight and Investigation Committee on Physicians' Role in Escalating Health Care Costs, April 5, 1978.

48. Wolfe, S. and Gordon, B.: Testimony before the Senate Health Subcommittee Hearings on Drug Reform Act of 1978, S.2755, April 12, 1978.

49. Wolfe, S.: Statement before HRG hearing on the Birth Control Pill; Risks, Alternatives, Recommendations, May 18, 1978.

50. Wolfe, S.: Testimony before the House Health Subcommittee Hearings on H.R. 11611, the Drug Reform Bill, June 13, 1978.

51. Wolfe, S. and Stulberg, R.B.: Testimony before the Consumer Product Safety Commission concerning the proposed ban on the products containing benzene, June 14, 1978.

52. Wolfe, S.: Statement before the D.C. Fire Marshall hearings on Ionization or Radioactive Smoke Detectors, July 28, 1978.

53. Wolfe, S. and Stulberg, R.B.: Testimony before the Subcommittee on Labor of the Committee on Human Resources, U.S. Senate. Topic: OSHA's performance in general terms, October 31, 1978.

54. Wolfe, S.: Testimony before the Subcommittee on Monopoly, Senate Small Business Hearings on Darvon, January 31, 1979.

55. Wolfe, S.: Testimony before FDA Drug Abuse Advisory Commission on Darvon, February 13, 1979.

56. Wolfe, S.: Testimony before FDA Endocrinology and Metabolism Advisory Committee on clofibrate, February 15, 1979.

57. Wolfe, S.: Testimony before the Senate Health Subcommittee Oversight Hearings on the National Cancer Program, March 7, 1979.

58. Wolfe, S.: Testimony before FDA Hearings on Darvon, April 6, 1979.

59. Wolfe, S.: Testimony before FDA Drug Abuse Advisory Committee Hearings on Darvon, April 17, 1979.

60. Wolfe, S., Bogue, T. and Sigelman, D.W.: Testimony before the Subcommittee on Government Information and Individual Rights of the House Committee on Interstate and Foreign Commerce on HR 2979, The Federal Privacy of Medical Records Act, July 9, 1979.

61. Wolfe, S.: Testimony before Senate Health Subcommittee on Estrogen use, August 1, 1979.

62. Wolfe, S., Sigelman, D.W., and Vladeck, D.C.: Testimony before the House Commerce Health and the Environment Subcommittee on proposed exemptions of Professional Standards Review Organizations (PSRO's) from the Freedom of Information Act, October 25, 1979.

63. Wolfe, S.: Testimony before the House Subcommittee on Crime on H.R. 4973, February 4, 1980.

64. Wolfe, S.: Testimony before the House Health Subcommittee hearings on Propoxyphene, May 21, 1980.

65. Wolfe, S. and Sobel, P.: Statement before the FDA Drug Abuse Advisory Committee on DEA recommendations for Rescheduling Anti-Obesity Drugs Phendimetrazine, Diethylpropion and Phentermine in Schedule II, November 17, 1980.

66. Wolfe, S., Sobel, P. and Bargmann, E.: Testimony before the FDA Endocrinologic and Metabolic Drugs Advisory Committee on Clofibrate and cholesterol-lowering drugs, Jan. 12, 1981.

67. Wolfe, S. and Sigelman, D.W.: Testimony before the Institute of Medicine Panel on PSRO Data Disclosure Policy, Feb. 12, 1981.

68. Wolfe, S.: Testimony before the House Oversight and Investigation Subcommittee hearings on government disruption of generic drug approval, March 10, 1981.

69. Wolfe, S. and Behrman, M.: Testimony before the Consumer Product Safety Commission hearings on Urea-Formaldehyde Foam Insulation, March 20, 1981.
70. Wolfe, S., Gordon, B. and Schultz, W.B.: Testimony before the House Health Subcommittee hearings on lengthening the duration of patents for drugs, April, 1981.
71. Wolfe, S. and Bargmann, E: Testimony before the Ad Hoc Advisory Committee on Erythromycin Estolate, April 16, 1981.
72. Wolfe, S: Testimony before the U.S. Senate Committee on the Judiciary on S.255 which seeks to extend the patent period for drugs, April 30, 1981.
73. Wolfe, S., Levin, J.D. and Sobel, P.: Testimony before the Drug Abuse Advisory Committee Meeting on Benzodiazepines, May 14, 1981.
74. Wolfe, S., LaCheen, C. and Bargmann, E.: Testimony before the Subcommittee on Oversight and Investigations on Potassium Iodide's Role in Emergency Planning for a Nuclear Accident, March 5, 1982.
75. Wolfe, S. and Greenberg, A.: Testimony before the Senate Consumer Hearings on Product Liability, March 9, 1982.
76. Wolfe, S. and Greenberg, A.: Testimony before the Subcommittee on Energy and Commerce on FDA's Bureau of Medical Devices, July 16, 1982.
77. Wolfe, S.: Testimony before the House Subcommittee on Health and Long-Term Care Hearings on the Safety and Efficacy of Over-The-Counter Drugs, July 21, 1983
78. Wolfe, S.: Testimony before the Occupational Safety and Health Administration on OSHA's Proposed Ethylene Oxide rule, July 22, 1983.
79. Wolfe, S., Bargmann, E., and Levin J.: Statement before the Consensus Development Conference on Drugs and Insomnia: The use of Medications to Promote Sleep, November 15, 1983.
80. Wolfe, S.: Testimony before the House of Representatives on the health and ethical considerations of exporting unapproved drugs, July 27, 1984.

81. Wolfe, S.: Testimony before House Health Subcommittee hearings on H.R. 1381 requiring warning labels, advertisements and store signs concerning Aspirin and Reye's Syndrome, March 15, 1985.
82. Wolfe, S., Torrey, E. Fuller, Bargmann, Eve: Testimony before the D.C. City Council Consumer and Regulatory Affairs Committee on Consideration of the D.C. Health Occupations Revision Act, October 30, 1985.
83. Wolfe, S.: Testimony before the New York City Council Hearing on Medical Malpractice, January 21, 1986.
84. Wolfe, S., Claybrook, Joan B.: Testimony before the Maryland House of Delegates Hearing on Medical Malpractice, February 19, 1986.
85. Wolfe, S., Abrams, L.: Testimony on OSHA's proposed Benzene Standard, March 6, 1986.
86. Wolfe, S., Abrams, L.: Testimony on OSHA's proposed rule for occupational exposure to Formaldehyde, Docket H-225A, March 24, 1986.
87. Wolfe, S.: Testimony before Senate Health Subcommittee Hearings on Medical Malpractice, May 7, 1986.
88. Wolfe, S.: Testimony before Civil and Constitutional Rights Subcommittee House Judiciary Committee Hearing on H.R. 5540 Health Care Quality Improvement Act of 1986 on Medical Malpractice, October 8, 1986.
89. Wolfe, S.: Testimony before the Subcommittee on Health and the Environment House Committee on Energy and Commerce on Medical Device Regulation, May 4, 1987.
90. Wolfe, S.: Testimony on product liability before the Subcommittee on Commerce, Consumer Protection and Competitiveness, House Committee on Energy and Commerce, August 6, 1987.
91. Wolfe, S.: Testimony on regulating care of Medicare recipients before the Subcommittee on Peer Review Organizations, House Committee on Energy and Commerce, October 26, 1987.

92. Wolfe, S., Tanio C.: Statement on birth control pills before the FDA Workshop on Birth Control Pills, January 15, 1988.
93. Wolfe, S.: Testimony on silicone gel implants before the FDA Advisory Committee on General and Plastic Surgery Devices, November 22, 1988.
94. Wolfe, S. and Holmes, A.: Testimony on Accutane before the FDA Dermatologic Drugs Advisory Committee, May 8, 1989.
95. Holmes, A. and Wolfe S.: Testimony on Accutane before the FDA Fertility and Maternal Health Drugs Advisory Committee, June 1, 1989.
96. Wolfe, S.: Testimony on Philip Morris Bill of Rights Ads before the Subcommittee on Transportation and Hazardous Materials, House Committee on Energy and Commerce, November 16, 1989.
97. Wolfe, S.: Testimony on Guidelines for approving Nonsteroidal Antiinflammatory Drugs (NSAIDS) for Over-The-Counter Use, before the FDA Arthritis Drugs Advisory Committee, February 22, 1990.
98. Wolfe, S.: Testimony on Maryland Senate Bill 658: Triplicate Prescriptions for Controlled Prescription Drugs, March 13, 1990.
99. Wolfe, S. and Gilbert P. on S.1400 Product Liability Reform Act before the Subcommittee on Consumer Affairs, Senate Committee on Commerce, Science and Transportation, May 10, 1990.
100. Wolfe, S.: Testimony on Accutane before the FDA Joint Fertility and Maternal Health and Dermatologic Drug Advisory Committees, May 21, 1990.
101. Wolfe, S.: Testimony on H.R. 3095: Medical Device Amendments before the Subcommittee on Health, House Committee on Energy and Commerce, July 17, 1990.
102. Wolfe, S.: Testimony on the Medical Device Improvement Act before the Senate Committee on Labor and Human Resources, July 25, 1990.
103. Wolfe, S.: Testimony on Proposed Legislation to Require Triplicate Prescriptions for all Controlled Substance Prescription Drugs before the Subcommittee on Health, House Committee on Energy and Commerce, September 14, 1990.

104. Wolfe, S.: Testimony on Promotional Practices in the Pharmaceutical Industry before the Senate Committee on Human Resources, December 11, 1990.
105. Wolfe, S.: Testimony on the Role of Menopause and Gender Differences in Aging on the Development of Disease in Mid-Life and Older Women before the Senate Subcommittee on Aging, April 19, 1991.
106. Wolfe, S.: Testimony on Food, Drug, Cosmetic and Device Enforcement Amendments of 1991 before the House Subcommittee on Health and the Environment, July 16, 1991.
107. Wolfe, S.: Testimonies on Silicone Gel Breast Implants before the FDA Advisory Committee on General and Plastic Surgery Devices, November 12, 1991 and February 19, 1992.
108. Wolfe, S.: Testimony on Weakening the Drug Approval Process before the House Human Resources and Intergovernmental Operations Subcommittee, March 19, 1992.
109. Wolfe, S.: Testimony on Halcion before the FDA Psychopharmacologic Drugs Advisory Committee, May 18, 1992.
110. Wolfe, S.: Testimony on Amendments to Increase FDA Enforcement Authority before the Senate Labor and Human Resources Committee, May 19, 1992.
111. Wolfe, S.: Testimony on Nicotine Patches before the FDA Drug Abuse Advisory Committee, July 14, 1992.
112. Wolfe, S., Lurie, P. Testimony on Anti-Diarrheal Drugs before the FDA Over-the-Counter Advisory Committee Meeting, April 9, 1993.
113. Wolfe, S. on Barriers to Consumer Access to Health Information before the Subcommittee on Regulation, Business Opportunities and Technology, June 28, 1993.
114. Wolfe, S. Testimony on Fentanyl Lollipops before the FDA Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Abuse Advisory Committee, August 24, 1993.

115. Wolfe, S. Testimony on Clinical Investigator Conflict of Interest before the FDA Science Board Hearing, September 9, 1993.

116. Wolfe, S. Testimony on Pediatric Sedation before FDA Advisory Committee on Pediatric Sedation, March 1, 1994.

117. Wolfe, S. Testimony at Senate Judiciary Committee Confirmation Hearings on Judge Stephen Breyer, July 15, 1994.

118. Wolfe, S. Testimony before the Committee on Appropriations, Subcommittee on Agriculture, Rural Development and Related Agencies Hearing on FDA Appropriations, January 31, 1995.

119. Wolfe, S. Testimony before the FDA Arthritis Advisory Committee on the Petition to Ban Piroxicam (Feldene), October 11, 1995.

120. Wolfe, S. Testimony at FDA Hearing on Direct-to-Consumer Advertising of Prescription Drugs, October 19, 1995.

121. Wolfe, S. Testimony before the House Subcommittee on Health and the Environment Hearings on H.R.s 3199-3201, May 2, 1996.

122. Wolfe, S. Testimony before the Senate Labor and Human Resources Committee Hearing on FDA Performance, Efficiency and Use of Resources, April 11, 1997.

123. Wolfe, S., & Lurie, P. Testimony before the Subcommittee on Human Resources, Committee on Government Reform and Oversight, U.S. House of Representatives, on HIV Vaccine Trials and Needle Exchange Programs, May 8, 1997.

124. Wolfe, S. Testimony before the District of Columbia Control Board on Medical Malpractice, February 18, 1998.

125. Wolfe, S., & Lurie, P. Testimony before the Committee on Government Reform and Oversight, U.S. House of Representatives, on Inappropriate Use of Placebos in Human Experiments, April 22, 1998.

126. Wolfe, S. Statement before the Institute of Medicine Committee on the Safety of Silicone Breast Implants, July 24, 1998.

127. Wolfe, S. & Sasich, L. Statement before the FDA's Arthritis Drugs Advisory Committee on the Non-Steroidal Anti-Inflammatory Drug (NSAID) on Celecoxib Celebrex, December 1, 1998.
128. Wolfe, S. Statement before the FDA Science Forum on Biotechnology, December 9, 1998.
129. Wolfe, S. & Sasich, L. Statement before the FDA's Cardiovascular and Renal Drugs Advisory Committee on dofetilide (Tikosyn), January 28, 1999.
130. Wolfe, S. Statement before the FDA Endocrine and Metabolic Drugs Advisory Committee Meeting on Troglitazone, March 26, 1999.
131. Wolfe, S. Testimony concerning the Safety Issues Associated with Dietary Supplement Use During Pregnancy, March 30, 2000.
132. Wolfe, S. Testimony before the FDA Endocrinologic/Metabolic Advisory Committees on Switching Prescription to Nonprescription Drugs, July 13, 2000.
133. Wolfe, S., Sasich, L., Lurie, P., & Barbehenn, E. Testimony before the FDA on the Removal of Lotronex from the Market, August 31, 2000.
134. Wolfe, S. Testimony before the FDA on Safety Issues of Phenylpropanolamine (PPA), October 18, 2000.
135. Wolfe, S. & Sasich, L. Statement before the FDA's Arthritis Drugs Advisory Committee on the Nonsteroidal Anti-Inflammatory Drugs (NSAID) Celecoxib and Rofecoxib, January 7, 2001.
136. Wolfe, S. Testimony before the House of Representatives Committee on Government Reform Hearing on Dietary Supplements, March 20, 2001.
137. Wolfe, S. & Sasich, L. Testimony before the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee on a petition to relabel doxazosin (Cardura), May 24, 2001.
138. Wolfe, S. Testimony before the Subcommittee on Consumer Affairs, Senate Commerce Committee Hearing on Direct-to-Consumer (DTC) Advertising, July 24, 2001.

139. Wolfe, S. Testimony before the FDA Endocrine and Metabolic Drugs Advisory Committee Meeting on Pramlintide (SYMLIN), July 26, 2001.
140. Wolfe, S. & Sasich, L. Testimony before FDA Hearing on Risk Management of Prescription Drugs, May 22, 2002.
141. Wolfe, S. Testimony before the FDA Gastrointestinal Drugs and Drug Safety Advisory Committees Hearing on Alosetron, April 23, 2002.
142. Wolfe, S. Testimony Before Senate Governmental Affairs Committee, Subcommittee on Oversight of Government Management Hearing on Dangers of Ephedra, October 8, 2002.
143. Wolfe, S. Statement before the FDA Endocrinologic and Metabolic Drugs Advisory Committee Hearing on Rosuvastatin, July 9, 2003.
144. Wolfe, S. Statement before FDA Hearing on Silicone Gel Breast Implants, October 14, 2003.
145. Testimony before FDA advisory committee concerning alosetron (Lotronex), May 5, 2004
146. Testimony Before the FDA Reproductive Health Advisory Committee Concerning the Transdermal Testosterone Patch, December 02, 2004
147. Congressional Testimony by Sidney Wolfe M.D. on Current Issues Related to Medical Liability Reform, February 10, 2005
148. Testimony to FDA on Dangers of Cox-2 Drugs, February 17, 2005
149. Testimony before the Committee on Health Hearing on the Performance of the DC Board of Medicine, May 23, 2005
150. Statement by Sidney Wolfe, MD, at the Public Hearing on CDER's Current Risk Communication Strategies for Human Drugs, December 7, 2005
151. Statement Before the Institute of Medicine Committee Assessing the U.S. Drug Safety System, January 19, 2006
152. Testimony Before the FDA Advisory Committees on Possible Switch of Orlistat (XENICAL) to OTC Status, January 23, 2006

153. Statement Before the Institute of Medicine Committee on Developing Cancer Biomarkers: A Case Study Involving ACF/orlistat, June 15, 2006.
154. Testimony before the FDA Arthritis Advisory Committee concerning Arcoxia, April 12, 2007
155. Testimony Before FDA Advisory Committee Meeting on Rimonabant, June 13, 2007
156. Testimony Before the FDA Advisory Committee Meeting on Rosiglitazone, July 30, 2007
157. Testimony Before the Senate Judiciary Committee on Oxycontin and the Prosecution of Purdue, July 31, 2007
158. Testimony of Sidney M. Wolfe M.D. before the FDA on Behind-the-Counter Availability of Certain Drugs, November 14, 2007
159. Testimony before FDA advisory committee on the public health dangers of making lovastatin (MEVACOR) available over-the-counter, December 13, 2007